a) Progression free and b) overall survival probability of patients... | Download Scientific Diagram
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry | Prostate Cancer and Prostatic Diseases
Pharmaceutics | Free Full-Text | Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using 177Lu-iPSMA and 177Lu-DOTATOC: Experience after 905 Treatment Doses
mCRPC: PREVAIL Trial | HCP Site | XTANDI® (enzalutamide)
Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study | In Vivo
PROpel Trial Efficacy – LYNPARZA® (olaparib) for BRCAm mCRPC
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis–Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting - European Urology ...
Latest developments in prostate cancer treatment
Overall survival. mCRPC metastatic castration-resistant protate cancer.... | Download Scientific Diagram
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with 18F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort Study | Journal of Nuclear Medicine
ASCO GU 2022: Overall Survival after Progression on First Novel Hormonal Therapy in Patients with Metastatic Castration-Sensitive Versus Castration-Resistant Prostate Cancer (mCSPC Versus mCRPC)
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
ASCO 2020: CARD: Overall Survival Analysis of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel versus Abiraterone
Real World Patterns of PSA Response and Survival with Abiraterone and Enzalutamide in Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Clinical Oncology and Research | Science Repository | Open Access
Efficacy I PLUVICTO
Understanding what matters to metastatic castration‐resistant prostate cancer (mCRPC) patients when considering treatment options: A US patient preference survey - George - 2023 - Cancer Medicine - Wiley Online Library
Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study - Nakajima - 2021 - International
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort | British Journal of Cancer
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design -
Targeted Alpha Therapy Optimising Survival in Advanced Prostate Cancer
Progression-free survival of mCRPC patients treated with AAP | Download Scientific Diagram
Overall Survival (OS) for mCRPC patients treated with docetaxel for a... | Download Scientific Diagram
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC - Medical Conferences
